A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients
Crossref DOI link: https://doi.org/10.1007/s12325-016-0312-y
Published Online: 2016-03-12
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chastek, Benjamin
White, John
Van Voorhis, Damon
Tang, Derek
Stolshek, Bradley S.
Funding for this research was provided by:
This study was funded by Immunex, a wholly owned subsidiary of Amgen Inc. and by Wyeth, which was acquired by Pfizer in October 2009.